OTCQB:VVCIF - Post by User
Post by
1hot-techwomanon Jul 12, 2017 5:00pm
269 Views
Post# 26462131
Interesting report found on Abcann :)
Interesting report found on Abcann :)High Yields Plus Consistent Product Equals Strong Medical Offering ABcann Global Corp. owns 100% of ABcann Medicinals, a Canadian medical marijuana company licensed to carry on business as a producer and seller of medical cannabis. ABcann has production facilities in Napanee, Ontario. We estimate that ABcann produces in excess of 250grams / square foot / annum among the highest yields within the Canadian sector. These yields are possible due to ABcanns computer-controlled growing environment that monitors and controls several growing variables to maximize growth and minimize or avoid disease. The Companys systems can produce a consistent environment which will result in a consistent chemical compound from plant to plant to and batch to batch. The goal is for the cannabinoid profile to be within 10% allowing ABcann to provide patients with a consistent medical experience with every order. Furthermore, this consistency puts ABcann in a strong positon for potential medical device partnerships and clinical trials that require pharma-grade consistency in its delivery. The initial facility at Vanluven currently has 1,000kg of annual capacity which is expected to double by the end of 2017 to 2,000kg. The Company also has a 65-acre property that is nearby its Kimmett property. Health Canada has granted a license to build a 70,000 sqft facility which is expected to produce 10,000kg to 20,000kg per annum depending on single or double-layered grow rooms. Not only does ABcann have a strong management team led by CEO, Aaron Keay and Chairman and Founder Ken Clement but also has an outstanding advisory board. This includes Dr. Raphael Mechoulam who is world-renowned in his work with medical cannabis. The Company has exported seed to the State Government of Australia and dried flower to Israel and we expect ABcann to begin shipping product to Germany this year. Management has a global export strategy to target an international medical cannabis market expected to be $55.8B by 2024.